



PMI RESEARCH & DEVELOPMENT

Study ZRHM-REXA-08-US **Clinical Study Report Appendix 16.1.10** **Publications Based on the Clinical Study**

Study Title:	A randomized, controlled, open-label, 3-arm parallel group, multi-center study to demonstrate reductions in exposure to selected smoke constituents in apparently healthy smokers switching to the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) or observing smoking abstinence, compared to continuing to use menthol conventional cigarettes, for 5 days in confinement and prolonged by 86 days in an ambulatory setting
Study Number:	ZRHM-REXA-08-US
Product Name:	Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)
Study Initiated (first subject screened):	17 December 2013
Study Completed (last subject last visit):	12 October 2014
Principal Investigator and Affiliation:	Dr William Lewis, Covance Dallas Site 1341 W. Mockingbird Ln., Suite 400E Dallas, TX 75247 Dr H. Frank Farmer, Covance Daytona Beach Site 1900 Mason Ave., Suite 140 Daytona Beach, FL 32117
Sponsor:	Philip Morris Products S.A. PMI Research & Development Quai Jeanrenaud 5 2000 Neuchâtel, Switzerland
Sponsor Signatories:	Christelle Haziza, PhD, Manager P1 Clinical Program, Clinical Scientist Guillaume de La Bourdonnaye, MEng, MSc, Biostatistician Andrea Donelli, Clinical Scientist Ruben Rosoky, MD PhD MFPM, Medical Safety Officer
Version:	30
Date:	47 Oct 2014

This study was conducted in accordance with Good Clinical Practice.

Confidentiality Statement

This document is confidential. Disclosure of any of its contents to third parties is not permitted except by the prior written consent of Philip Morris Products S.A.



TABLE OF CONTENTS

16.1.10 PUBLICATIONS BASED ON THE CLINICAL STUDY	3
--	---



16.1.10 PUBLICATIONS BASED ON THE CLINICAL STUDY

The present study has been posted on the clinical trial registry website “www.clinicaltrials.gov”. Publication with the number: ID: NCT01989156. The brief title is “Reduced exposure study using THS 2.2 Menthol with 5 days in a confinement setting followed by 86 days in an ambulatory setting”.